Authors: J. Novák Authors‘ workplace: Urologická klinika VFN, Praha, přednosta prof. MUDr. J. Dvořáček, DrSc Published in: Prakt. Lék. 2001; (7): 396-399 Category:
772 patients from 68 urological departments took part in the study with alfuzosin 2.5 mg threetimes daily for treatment symptoms of BPH. The study lasted 3 months. The results andpatients’ quality of life were compared with the IPSS score and AUA symptom score. Adverseevents were minimal. The number of orthostatic hypotension was relatively low (1.8%). Thebenefit of the treatment for the patients with BPH treated with alfuzosin 2.5 mg t.i.d. wasrelatively good with a minimal number of adverse events.
Key words: NPH - study - alfuzosin.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
